Status:
COMPLETED
Post-Marketing Surveillance of Lenvima in Korean Patients
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Differentiated Thyroid Carcinoma (DTC)
Eligibility:
All Genders
Brief Summary
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participants who meet the following criteria will be eligible for inclusion in the study:
- Participants with approved indication for lenvatinib in Korea
- Participants who have written consent for use of personal and medical information for the study purpose
- Exclusion Criteria:
- Investigators will refer to approved indications and contraindications regarding exclusion criteria
Exclusion
Key Trial Info
Start Date :
November 10 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2021
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT02764554
Start Date
November 10 2016
End Date
September 29 2021
Last Update
October 7 2021
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Eisai Trial Site #18
Anyang, Gyeongji-do, South Korea
2
Eisai Trial Site #30
Bundang, Gyeongji-do, South Korea
3
Eisai Trial Site #14
Goyang, Gyeongji-do, South Korea
4
Eisai Trial Site #27
Goyang, Gyeongji-do, South Korea